Sumitomo Mitsui Trust Holdings, Inc. Intellia Therapeutics, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $145 Billion
- Q4 2024
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 2,992,663 shares of NTLA stock, worth $36.7 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,992,663
Previous 3,149,399
4.98%
Holding current value
$36.7 Million
Previous $64.7 Million
46.08%
% of portfolio
0.02%
Previous 0.05%
Shares
24 transactions
Others Institutions Holding NTLA
# of Institutions
336Shares Held
96.1MCall Options Held
1.06MPut Options Held
863K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$154 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$125 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$118 Million0.0% of portfolio
-
State Street Corp Boston, MA5.21MShares$63.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.81MShares$46.7 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $931M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...